Abstract
Background
The prognostic significance of tumor-infiltrating lymphocytes (TILs) has been established in breast cancers with estrogen receptor (ER)-negative and human epithelial growth factor receptor 2 (HER2)-negative or HER2-positive subtypes; however, its utility concerning the ER + /HER2 - subtype remains unclear.Methods
We evaluated the prognostic value of TILs by analyzing 717 invasive breast cancer operation cases. TILs were classified into three groups based on the proportion of area within the tumor: low ( < 10%), intermediate (10-50%), and high ( > 50%). Disease-free survival (DFS) and overall survival (OS) were calculated according to TIL levels.Results
Although there was no significant association between TIL levels and DFS or OS in all patients, high TILs were significantly associated with favorable DFS in Ki67-high (n = 238, p = 0.035) but not in Ki67-low (n = 470, p = 0.46) breast cancers. Multivariable analysis showed that high TILs were a significant and independent factor for DFS (HR 0.34; 95% CI 0.10-0.87; p = 0.023) among the Ki67-high group. In the ER + /HER2 - subtype, high-TILs showed favorable DFS in the Ki67-high group, although this was not statistically significant (p = 0.48); in contrast, unfavorable DFS was observed in the Ki67-low group (p = 0.027).Conclusions
In Ki67-high breast cancers, high TILs were associated with favorable DFS, irrespective of subtype, but increasing TIL levels correlated with worse DFS in the Ki67-low group with the ER + /HER2 - subtype. These results highlight variation in TIL prognostic significance between Ki67-high and -low breast cancers, particularly for the ER + /HER2 - subtype.Citations & impact
Impact metrics
Citations of article over time
Smart citations by scite.ai
Explore citation contexts and check if this article has been
supported or disputed.
https://scite.ai/reports/10.1007/s12282-019-00977-0
Article citations
Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing?
ESMO Open, 9(9):103695, 09 Sep 2024
Cited by: 0 articles | PMID: 39255535 | PMCID: PMC11415669
Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.
iScience, 27(8):110425, 29 Jun 2024
Cited by: 0 articles | PMID: 39206149 | PMCID: PMC11357803
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Breast Cancer Res, 26(1):41, 11 Mar 2024
Cited by: 1 article | PMID: 38468323 | PMCID: PMC10926638
The Value of Tumor Infiltrating Lymphocytes (TIL) for Predicting the Response to Neoadjuvant Chemotherapy (NAC) in Breast Cancer according to the Molecular Subtypes.
Biomedicines, 11(11):3037, 13 Nov 2023
Cited by: 4 articles | PMID: 38002037
The immune microenvironment characterisation and dynamics in hormone receptor-positive breast cancer before and after neoadjuvant endocrine therapy.
Cancer Med, 12(17):17901-17913, 08 Aug 2023
Cited by: 1 article | PMID: 37553911 | PMCID: PMC10524081
Go to all (12) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Breast Cancer Res Treat, 168(1):135-145, 22 Nov 2017
Cited by: 19 articles | PMID: 29168063
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Breast Cancer Res, 22(1):47, 14 May 2020
Cited by: 12 articles | PMID: 32408905 | PMCID: PMC7227091
Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
BMC Cancer, 20(1):1150, 25 Nov 2020
Cited by: 57 articles | PMID: 33238978 | PMCID: PMC7690150
Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Horm Mol Biol Clin Investig, 32(2):/j/hmbci.2017.32.issue-2/hmbci-2017-0022/hmbci-201, 22 Sep 2017
Cited by: 15 articles | PMID: 28937963
Review
Funding
Funders who supported this work.
Ministry of Education, Culture, Sports, Science, and Technology of Japan (1)
Grant ID: 15K10077